Do you want to read an article? Please log in or register.
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review
Lymphoma
Related content
Lymphoma
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Lancet Haematol.
Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM
doi: 10.1016/S2352-3026(20)30221-0.
RECOMMENDED
Lymphoma
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial
★ 3
Recommended by
Alexander Meisel, Faculty Member
Lancet Haematol.
Cheson BD, Bartlett NL, LaPlant B, Lee HJ, Advani RJ, Christian B, Diefenbach CS, Feldman TA, Ansell SM
doi: 10.1016/S2352-3026(20)30275-1.Visit the original publication at ncbi.nlm.nih.gov
Further Publications
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study
Lancet Haematol
Lynch RC, Cassaday RD, Smith SD, Fromm JR, Cowan AJ, Warren EH, Shadman MS, Shustov A, Till BG, Ujjani CS, Libby EN 3rd, Philip M, Coye H, Martino CN, Bhark SL, Morris K, Rasmussen H, Behnia S, Voutsinas J, Gopal AK
doi: 10.1016/S2352-3026(21)00170-8
Lymphoma
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Drugs.
Scott LJ
doi: 10.1007/
Lymphoma
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis
Lancet Haematol.
Linschoten M, Kamphuis JAM, van Rhenen A, Bosman LP, Cramer MJ, Doevendans PA, Teske AJ, Asselbergs FW
doi: 10.1016/S2352-3026(20)30031-4.
Lymphoma
Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group
Br J Haematol
Eichenauer DA, Müller H, Elger L, Goergen H, Fuchs M, Kreissl S, Böll B, Diehl V, von Tresckow B, Borchmann P, Engert A
doi: 10.1111/bjh.17327
Lymphoma
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
N Engl J Med.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ1, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group
doi: 10.1056/NEJMoa1708984.
Lymphoma
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Lancet Haematol.
Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J
doi: 10.1016/S2352-3026(19)30026-2.
Lymphoma
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
Lancet Oncol
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL, KEYNOTE-204 investigators.
doi: 10.1016/S1470-2045(21)00005-X